NCT02692742 - Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions

Chemotherapy-Induced NeutropeniaMyelosuppressionBreast Cancer

Interventions

DRUG

Myelo001

Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment

DRUG

Placebo

Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment

Trial Locations (23)

Site 20, Aachen

Site 16, Aurich

Site 21, Dresden

Site 26, Dresden

Site 05, Erlangen

Site 09, Esslingen am Neckar

Site 02, Frankfurt a.M.

Site 13, Frankfurt a.M.

Site 01, Friedrichshafen

Site 25, Goslar

Site 11, Hamburg

Site 10, Hanover

Site 22, Hanover

Site 07, Konstanz

Site 29, Lübeck

Site 03, Mainz

Site 23, Mainz

Site 04, Offenbach

Site 19, Oldenburg

Site 17, Ravensburg

Site 24, Rosenheim

Site 28, Tübingen

Site 12, Westerstede